Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Effects of ipriflavone on postmenopausal syndrome and osteoporosis.

Zhang X, Li SW, Wu JF, Dong CL, Zheng CX, Zhang YP, Du J.

Gynecol Endocrinol. 2010 Feb;26(2):76-80. doi: 10.3109/09513590903184159.

PMID:
19672742
[PubMed - indexed for MEDLINE]
2.

Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.

Kovács AB.

Agents Actions. 1994 Mar;41(1-2):86-7.

PMID:
8079827
[PubMed - indexed for MEDLINE]
3.

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.

Gennari C, Adami S, Agnusdei D, Bufalíno L, Cervetti R, Crepaldi G, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Mazzuoli GF, Ortolani S, Passeri M, Serni U, Vecchiet L.

Calcif Tissue Int. 1997;61 Suppl 1:S19-22.

PMID:
9263612
[PubMed - indexed for MEDLINE]
4.

Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.

Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.

Eur Cytokine Netw. 2007 Sep;18(3):148-53. Epub 2007 Sep 7.

PMID:
17823083
[PubMed - indexed for MEDLINE]
5.

Ipriflavone for the treatment of osteoporosis.

Choi YK, Han IK, Yoon HK.

Osteoporos Int. 1997;7 Suppl 3:S174-8. No abstract available.

PMID:
9536327
[PubMed - indexed for MEDLINE]
6.

Miscellaneous and experimental agents.

Reginster JY.

Am J Med Sci. 1997 Jan;313(1):33-40. Review.

PMID:
9001164
[PubMed - indexed for MEDLINE]
7.

Efficacy of ipriflavone in established osteoporosis and long-term safety.

Agnusdei D, Bufalino L.

Calcif Tissue Int. 1997;61 Suppl 1:S23-7.

PMID:
9263613
[PubMed - indexed for MEDLINE]
8.

Design for an ipriflavone multicenter European fracture study.

Reginster JY, Bufalino L, Christiansen C, Devogelaer JP, Gennari C, Riis BJ, Roux C.

Calcif Tissue Int. 1997;61 Suppl 1:S28-32.

PMID:
9263614
[PubMed - indexed for MEDLINE]
9.

Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.

Gambacciani M, Cappagli B, Piaggesi L, Ciaponi M, Genazzani AR.

Calcif Tissue Int. 1997;61 Suppl 1:S15-8.

PMID:
9263611
[PubMed - indexed for MEDLINE]
10.

The future of ipriflavone in the management of osteoporotic syndromes.

Avioli LV.

Calcif Tissue Int. 1997;61 Suppl 1:S33-5. Review. No abstract available.

PMID:
9263615
[PubMed - indexed for MEDLINE]
11.

Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.

Fujita T, Fujii Y, Miyauchi A, Takagi Y.

J Bone Miner Metab. 1999;17(4):289-95.

PMID:
10575594
[PubMed - indexed for MEDLINE]
12.

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators.

N Engl J Med. 2003 Sep 25;349(13):1207-15. Epub 2003 Sep 20.

PMID:
14500804
[PubMed - indexed for MEDLINE]
Free Article
13.

Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial.

Wu J, Oka J, Ezaki J, Ohtomo T, Ueno T, Uchiyama S, Toda T, Uehara M, Ishimi Y.

Menopause. 2007 Sep-Oct;14(5):866-74.

PMID:
17464237
[PubMed - indexed for MEDLINE]
14.

Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.

Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, Cappelli N, Fioretti P.

J Endocrinol Invest. 1993 May;16(5):333-7.

PMID:
8320424
[PubMed - indexed for MEDLINE]
15.

Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women.

De Leo V, Ditto A, la Marca A, Lanzetta D, Massafra C, Morgante G.

Calcif Tissue Int. 2000 Apr;66(4):263-7.

PMID:
10742442
[PubMed - indexed for MEDLINE]
16.

Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis.

Dempster DW.

J Bone Miner Res. 1997 Aug;12(8):1152-4. Review. No abstract available.

PMID:
9258744
[PubMed - indexed for MEDLINE]
17.

Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.

Agnusdei D, Gennari C, Bufalino L.

Osteoporos Int. 1995;5(6):462-6.

PMID:
8695969
[PubMed - indexed for MEDLINE]
18.

Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study.

Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F; PHYTOS Investigators.

Am J Clin Nutr. 2008 Mar;87(3):761-70.

PMID:
18326616
[PubMed - indexed for MEDLINE]
Free Article
19.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
[PubMed - indexed for MEDLINE]
20.

Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis.

Horowitz M, Wishart JM, Need AG, Morris HA, Nordin BE.

Clin Endocrinol (Oxf). 1993 Dec;39(6):649-55.

PMID:
8287582
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk